2007
DOI: 10.1093/eurheartj/ehm456
|View full text |Cite
|
Sign up to set email alerts
|

The role of endomyocardial biopsy in the management of cardiovascular disease: A Scientific Statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology Endorsed by the Heart Failure Society of America and the Heart Failure Association of the European Society of Cardiology

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

5
638
0
66

Year Published

2008
2008
2022
2022

Publication Types

Select...
10

Relationship

0
10

Authors

Journals

citations
Cited by 657 publications
(729 citation statements)
references
References 134 publications
5
638
0
66
Order By: Relevance
“…To overcome these diagnostic difficulties, endomyocardial biopsy (EMB) with immunohistochemistry is a further diagnostic option, which is widely accepted in the diagnostic cascade of myocardial inflammation. The overall complication rate of EMB is described as 6 % with severe complications appearing in 0.1 % to 0.5 % [25]. Considering the addressed risks in conjunction with its invasive character, EMB seems not to be justifiable in patients with less severe disease stages.…”
Section: Myocardial Inflammationmentioning
confidence: 99%
“…To overcome these diagnostic difficulties, endomyocardial biopsy (EMB) with immunohistochemistry is a further diagnostic option, which is widely accepted in the diagnostic cascade of myocardial inflammation. The overall complication rate of EMB is described as 6 % with severe complications appearing in 0.1 % to 0.5 % [25]. Considering the addressed risks in conjunction with its invasive character, EMB seems not to be justifiable in patients with less severe disease stages.…”
Section: Myocardial Inflammationmentioning
confidence: 99%
“…In contrast, the most recent study showed that the major complication rate for left ventricular endomyocardial biopsies is 0.64% and that for right ventricular endomyocardial biopsies is 0.82%, thus indicating a lower risk compared with previous reports (14). The recently published guidelines of the American Heart Association, the American College of Cardiology and the European Society of Cardiology state that new-onset heart failure of two weeks duration associated with a normal-sized or dilated left ventricle and hemodynamic compromise is a class I indication for a left ventricular endomyocardial biopsy (15). In the present case, the patient's vital signs were stable during the early phase of the clinical course, and after the hemodynamic compromise occurred, performing an endomyocardial biopsy was of considerable risk due to severe thrombocytopenia.…”
Section: Discussionmentioning
confidence: 75%
“…This assay requires a small sample such that precious cardiac tissues from biopsies or donors can be assayed. Biopsy is routinely performed for diagnosis of the presence and/or etiology of cardiomyopathy (61)(62)(63). It has a Ͻ1% complication rate (62).…”
Section: Discussionmentioning
confidence: 99%